A Phase 2 interventional study of XmAb5871 and Placebo to match XmAb5871 in Systemic Lupus Erythematosus, sponsored by Xencor, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by Xencor, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 163rd largest by enrollment of the 407 interventional ones that give a count, is one of 11 that started in 2016, is one of 120 in phase 2, and was the 217th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
Xencor, Inc. is the lead sponsor of 30 studies on the registry; 7 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 2 (13%) have results posted.
Xencor, Inc. has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
XmAb5871 administered by IV infusion for up to a total of 16 infusions
Biological: XmAb5871
Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
Biological: Placebo to match XmAb5871
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225
Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 225
Time frame: Day 225
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169
Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169
Time frame: Day 169
Time to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients
Loss of improvement was defined as worsening of disease activity that in the opinion of the principal investigator requires a change in treatment (exclusive of a decrease in oral steroids) AND one of: 1. SELENA- SLEDAI increase of \>=4 points from maximal improvement OR 2. Worsening of at least 1 BILAG A or B score OR 3. New BILAG A or B score.
Time frame: From the date of randomization until the date of loss of Systemic Lupus Erythematosus Disease Activity Improvement, or the date of the final efficacy assessment, up to 239 days.
First informed consent date: 16FEB2016 First randomization date: 07MAR2016 Last informed consent date: 09NOV2017 Last randomization date: 07DEC2017
| Milestone | XmAb5871 | Placebo |
|---|---|---|
| Started | 53 | 52 |
| Completed | 28 | 17 |
| Not completed | 25 | 35 |
| Withdrew: Refused infusion (no study treatment) | 1 | 0 |
| Withdrew: Loss of improvement per protocol | 14 | 25 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: No documented disease improvement | 0 | 1 |
| Withdrew: Completed study under original protocol | 0 | 1 |
| Withdrew: Lack of response | 0 | 1 |
Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 225
| Participants | XmAb5871 | Placebo |
|---|---|---|
| Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 | 21 | 12 |
Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169
| Participants | XmAb5871 | Placebo |
|---|---|---|
| Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169 | 29 | 17 |
Loss of improvement was defined as worsening of disease activity that in the opinion of the principal investigator requires a change in treatment (exclusive of a decrease in oral steroids) AND one of: 1. SELENA- SLEDAI increase of \>=4 points from maximal improvement OR 2. Worsening of at least 1 BILAG A or B score OR 3. New BILAG A or B score.
| days | XmAb5871 | Placebo |
|---|---|---|
| Time to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients | 230 (197.0 to 239.0) | 131 (85.0 to 225.0) |
Collected over Adverse event summaries include events reported between randomization and the end of study visit (Day 253). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XmAb5871 | 0/52 (0%) | 7/52 (13.5%) | 41/52 (78.8%) |
| Placebo | 0/52 (0%) | 4/52 (7.7%) | 28/52 (53.8%) |
| Event | XmAb5871 | Placebo |
|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/52 | 0/52 |
| AnaemiaBlood and lymphatic system disorders | 0/52 | 1/52 |
| Atrial fibrillationCardiac disorders | 1/52 | 0/52 |
| EnteritisGastrointestinal disorders | 0/52 | 1/52 |
| PyrexiaGeneral disorders | 1/52 | 0/52 |
| PneumoniaInfections and infestations | 1/52 | 0/52 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/52 | 0/52 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/52 | 1/52 |
| MigraineNervous system disorders | 0/52 | 1/52 |
| DizzinessNervous system disorders | 1/52 | 0/52 |
| Event | XmAb5871 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 20/52 | 9/52 |
| HeadacheNervous system disorders | 12/52 | 1/52 |
| VomitingGastrointestinal disorders | 9/52 | 1/52 |
| Back painMusculoskeletal and connective tissue disorders | 8/52 | 2/52 |
| DizzinessNervous system disorders | 8/52 | 1/52 |
| FlushingVascular disorders | 7/52 | 0/52 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 5/52 | 6/52 |
| Upper respiratory tract infectionInfections and infestations | 4/52 | 6/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/52 | 1/52 |
| Urinary tract infectionInfections and infestations | 5/52 | 3/52 |
Intent to Treat (ITT) Population: All patients who have received at least a partial dose of XmAb5871 or placebo. One patient was randomized to XmAb5871 but was never treated and withdrew from the study. This one patient is excluded from this analysis.
| Age, Continuous(years) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| Median | 45.5 (23 to 65) | 43.5 (20 to 64) | 45.0 (20 to 65) |
| Sex: Female, Male(Participants) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| Female | 50 | 49 | 99 |
| Male | 2 | 3 | 5 |
| Ethnicity (NIH/OMB)(Participants) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 46 | 48 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 26 | 25 | 51 |
| White | 19 | 25 | 44 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Region of Enrollment(participants) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| United States | 52 | 52 | 104 |
| SLEDAI Total Score at Screening--Efficacy Evaluable Population(units on a scale) | XmAb5871 | Placebo | Total |
|---|---|---|---|
| Median | 8.0 (4 to 16) | 10.0 (2 to 18) | 10.0 (2 to 18) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2016 to primary completion in Jul 2018, 29 months.
Results were first posted in Aug 2019, 1 year after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 29 months is close to that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obexelimab
Lupus Erythematosus, Systemic →